Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PNL013
MIFTS: 37

Penile Disease

Categories: Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Penile Disease

About this section

MalaCards integrated aliases for Penile Disease:

Name: Penile Disease 12 15
Penile Diseases 73

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:1529
ICD10 33 N48.8 N48.89
ICD9CM 35 607.8 607.89
SNOMED-CT 68 198558008
Sources

Summaries for Penile Disease

About this section
MalaCards based summary : Penile Disease, also known as penile diseases, is related to mental retardation, truncal obesity, retinal dystrophy, and micropenis syndrome and giant hemangioma, and has symptoms including pelvic pain An important gene associated with Penile Disease is PDE5A (Phosphodiesterase 5A), and among its related pathways/superpathways are Pathways in cancer and HTLV-I infection. The drugs Dexmedetomidine and Ropivacaine have been mentioned in the context of this disorder. Affiliated tissues include t cells, lymph node and bone.

Sources

Related Diseases for Penile Disease

About this section

Diseases related to Penile Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
# Related Disease Score Top Affiliating Genes
1 mental retardation, truncal obesity, retinal dystrophy, and micropenis syndrome 11.0
2 giant hemangioma 10.6 IFNA2 TGFB1
3 cutaneous polyarteritis nodosa 10.5 IFNA2 SMAD3
4 orbital plasma cell granuloma 10.5 IFNA2 MRAP
5 chronic orbital inflammation 10.5 IFNA2 MRAP
6 peyronie disease 10.3 IFNA2 PDE5A TGFB1
7 diffuse pulmonary fibrosis 10.3 MRAP SMAD2
8 hypochondrogenesis 10.2 SMAD2 SMAD3
9 polyarteritis nodosa 10.2 IFNA2 SMAD3
10 dupuytren contracture 10.2 DCN TGFB1
11 iritis 10.2 MRAP PHB2
12 iris disease 10.2 MRAP PEX19
13 spastic paraplegia 3, autosomal dominant 10.2 SMAD2 TGFB1
14 phimosis 10.2 PEX19 WASHC4
15 enthesopathy 10.2 MRAP PHB2
16 bursitis 10.2 MRAP PHB2
17 tendinitis 10.2 MRAP PHB2
18 urethritis 10.1 MRAP PHB2
19 transient arthritis 10.1 MRAP PHB2
20 hypertrophic scars 10.1 SMAD2 SMAD3 TGFB1
21 keloids 10.1 SMAD2 SMAD3 TGFB1
22 ureteral disease 10.1 SMAD2 SMAD3 TGFB1
23 urinary tract obstruction 10.1 SMAD2 SMAD3 TGFB1
24 renal fibrosis 10.0 SMAD2 SMAD3 TGFB1
25 urethral syndrome 10.0 MRAP PHB2
26 pulmonary fibrosis, idiopathic 9.9 SMAD2 SMAD3 TGFB1
27 penile cancer 9.9 IFNA2 WASHC4
28 localized scleroderma 9.9 DCN SMAD3 TGFB1
29 dysentery 9.8 IFNA2 PHB2
30 clear cell adenocarcinoma 9.7 SMAD2 SMAD3
31 peyronie's disease 9.6 DCN IFNA2 SMAD3 TGFB1
32 impotence 9.5
33 nephrogenic systemic fibrosis 9.5 DCN SMAD2 SMAD3 TGFB1
34 balanitis 9.3 MRAP PHB2 SLC5A2

Comorbidity relations with Penile Disease via Phenotypic Disease Network (PDN):


Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Penile Disease:



Diseases related to Penile Disease
Sources

Symptoms & Phenotypes for Penile Disease

About this section

UMLS symptoms related to Penile Disease:


pelvic pain
Sources

Drugs & Therapeutics for Penile Disease

About this section

Drugs for Penile Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 113775-47-6 68602 5311068
2
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 71273 175805
3
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
4 Anti-Allergic Agents Phase 4
5 Anti-Inflammatory Agents Phase 4,Phase 1,Not Applicable
6 Dermatologic Agents Phase 4,Phase 2
7 mometasone furoate Phase 4
8 Adrenergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
9 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Not Applicable
10 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2
11 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Not Applicable
12 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
13 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
14 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Anesthetics, Local Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Hypnotics and Sedatives Phase 4,Phase 3,Phase 2
18 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable
19 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3,Not Applicable
21 Respiratory System Agents Phase 4,Phase 2,Phase 3,Not Applicable
22 Hormone Antagonists Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
23 Hormones Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
25 glucocorticoids Phase 4,Not Applicable
26
Epinephrine Approved, Vet_approved Phase 2, Phase 3,Not Applicable 51-43-4 5816
27
Racepinephrine Approved Phase 2, Phase 3,Not Applicable 329-65-7 838
28
Atracurium Approved, Experimental, Investigational Phase 2, Phase 3 64228-79-1 47319
29
Atropine Approved, Vet_approved Phase 2, Phase 3 5908-99-6, 51-55-8 174174
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3,Phase 3 437-38-7 3345
31
Isoflurane Approved, Vet_approved Phase 2, Phase 3 26675-46-7 3763
32
Neostigmine Approved, Vet_approved Phase 2, Phase 3 59-99-4 4456
33
Nitrous oxide Approved, Vet_approved Phase 2, Phase 3,Not Applicable 10024-97-2 948
34
Thiopental Approved, Vet_approved Phase 2, Phase 3 76-75-5 3000715
35
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
36 Estradiol valerate Approved, Investigational, Vet_approved Phase 3 979-32-8
37
Polyestradiol phosphate Approved Phase 3 28014-46-2
38
Testosterone Approved, Investigational Phase 3,Phase 1,Early Phase 1 58-22-0 6013
39 Adrenergic beta-Agonists Phase 2, Phase 3,Not Applicable
40 Autonomic Agents Phase 2, Phase 3,Not Applicable
41 Bronchodilator Agents Phase 2, Phase 3,Not Applicable
42 Epinephryl borate Phase 2, Phase 3,Not Applicable
43 Mydriatics Phase 2, Phase 3,Not Applicable
44 Vasoconstrictor Agents Phase 2, Phase 3,Not Applicable
45 Adjuvants, Anesthesia Phase 2, Phase 3,Phase 3
46 Analgesics, Opioid Phase 2, Phase 3,Phase 3
47 Anesthetics, General Phase 2, Phase 3,Phase 3,Phase 1
48 Anesthetics, Intravenous Phase 2, Phase 3,Phase 3
49 Anti-Arrhythmia Agents Phase 2, Phase 3
50 Cholinergic Agents Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 Treatment of Phimosis With Topical Steroid Cream -Double-blind, Randomized, Placebo-controlled Study Unknown status NCT01108198 Phase 4 Mometasone furoate cream;moisturizing cream
2 Effects of Dexmedetomidine as Adjunct to Pudendal Block for Pediatric Penile Surgery Unknown status NCT02848157 Phase 4 Dexmedetomidine;plain ropivacaine;Ropivacaine
3 Pudendal Block Versus Caudal Block for Hypospadias Completed NCT02390388 Phase 4
4 Does Caudal Block Increase the Incidence of Urethrocutaneous Fistula Formation Following Hypospadias Repair in Infants? Recruiting NCT02861950 Phase 4 Caudal block with ropivacaine;penile nerve block with bupivacaine
5 Mild Versus Potent Corticosteroids as Treatment for Phimosis in Children Withdrawn NCT00933023 Phase 4 hydrocortisone;Betamethasone
6 An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease Completed NCT02267460 Phase 3
7 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01685437 Phase 3
8 A Study of AA4500 in Men With Peyronie's Disease Completed NCT01243411 Phase 3
9 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221623 Phase 3
10 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221597 Phase 3
11 Effectiveness of Caudal Epidural Block on Intraoperative Blood Loss During Hypospadias Repair Completed NCT02752308 Phase 2, Phase 3 Bupivacaine;Dilute epinephrine injection;Fentanyl;dextrose plus sodium chloride.;neostigmine and atropine
12 Dexmedetomidine Infusion in Hypospadias Surgery Completed NCT00926705 Phase 3 Dexmedetomidine and Fentanyl;Fentanyl
13 Local Oestrogen Versus Placebo as Preoperative Treatment in Patients With Severe Hypospadias: Effects on Post-operative Complications Completed NCT01370798 Phase 3 promestriene;Placebo
14 Phase II Study of Dietary Cholesterol for Smith-Lemli-Opitz Syndrome Unknown status NCT00004347 Phase 2
15 Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease Completed NCT01430169 Phase 2
16 The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Completed NCT00755222 Phase 2
17 A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis Completed NCT03114254 Phase 2 Cabazitaxel
18 Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer Completed NCT00066391 Phase 2 cisplatin;irinotecan hydrochloride
19 Association of Different Doses of Clonidine in Caudal Epidural Anesthesia for Hypospadias Surgery Completed NCT02769390 Phase 2 Clonidine 1 mcg/Kg;Clonidine 2 mcg/ Kg;Clonidine 3 mcg/ Kg
20 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
21 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
22 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Completed NCT01209325 Phase 2
23 Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia Completed NCT00940901 Phase 2 sildenafil
24 Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis Completed NCT00512096 Phase 2 Ifosfamide;Paclitaxel (Taxol);Cisplatin
25 Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome Completed NCT00272844 Phase 1, Phase 2 crystalline cholesterol oil-based suspension
26 Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome Completed NCT00114634 Phase 2
27 Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer Completed NCT00002506 Phase 2 isotretinoin
28 Simvastatin Therapy in Smith-Lemli-Opitz Syndrome Completed NCT00064792 Phase 2 Simvastatin Susp.;OraPlus
29 H-22411: BOTOX® for Peyronie's Disease Recruiting NCT00812838 Phase 2 100 units of Botulinum Toxin Type A
30 M7824 in Subjects With HPV Associated Malignancies Recruiting NCT03427411 Phase 2 M7824
31 HPV Anti-CD40 RNA Vaccine Recruiting NCT03418480 Phase 1, Phase 2 HPV vaccine
32 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
33 Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Recruiting NCT03012581 Phase 2 Nivolumab
34 Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis (AFU-GETUG 25) Recruiting NCT02817958 Phase 2 Chemotherapie TIP
35 Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS) Recruiting NCT01773278 Phase 2 Antioxidants;Cholesterol
36 Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis Recruiting NCT01728233 Phase 2 Dacomitinib
37 A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP) Active, not recruiting NCT02057913 Phase 2 Vinflunine
38 A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy Not yet recruiting NCT03391479 Phase 2 Avelumab
39 S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) Terminated NCT00058448 Phase 2 docetaxel
40 Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) Withdrawn NCT02014831 Phase 2 Cetuximab;TIP
41 Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia Withdrawn NCT00538564 Phase 2 tadalafil;placebo
42 Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD Completed NCT02395029 Phase 1
43 Peyronie's Disease Treatment Protocol Completed NCT02072018 Phase 1 H-100;Placebo
44 Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Completed NCT01578473 Phase 1 Vitamin D2;Vitamin E;Testosterone Pellets
45 Evaluating Pain Outcomes of Ketorolac Administration in Children Undergoing Circumcision Completed NCT02973958 Phase 1 Bupivacaine;Sevoflurane;Acetaminophen;Ibuprofen;Ketorolac
46 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
47 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
48 Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora Not yet recruiting NCT03463239 Phase 1
49 Foreskin Graft Tubularized Incised Plate Urethroplasty vs Tubularized Incised Plate for Primary Hypospadias (FGTIP-TIP) Unknown status NCT02497963 Not Applicable
50 Hypospadias and Exome: Identification of New Genes for Familial Hypospadias Unknown status NCT02495090 Not Applicable

Search NIH Clinical Center for Penile Disease

Sources

Genetic Tests for Penile Disease

About this section
Sources

Anatomical Context for Penile Disease

About this section

MalaCards organs/tissues related to Penile Disease:

41
T Cells, Lymph Node, Bone
Sources

Publications for Penile Disease

About this section

Articles related to Penile Disease:

# Title Authors Year
1
Vascular impotence: focal or diffuse penile disease. ( 1433544 )
1992
Sources

Variations for Penile Disease

About this section
Sources

Expression for Penile Disease

About this section
Search GEO for disease gene expression data for Penile Disease.
Sources

Pathways for Penile Disease

About this section

Pathways related to Penile Disease according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 37
12.63 IFNA2 SMAD2 SMAD3 TGFB1
2
HTLV-I infection 37
12.23 SMAD2 SMAD3 TGFB1
3
Endocytosis 37
12.21 SMAD2 SMAD3 WASHC4
4
Cell cycle 1 37
12.18 SMAD2 SMAD3 TGFB1
5
Proteoglycans in cancer 37
12.11 DCN SMAD2 TGFB1
6
Transcriptional activity of SMAD2/SMAD3-SMAD4 heterotrimer 66
Show member pathways
 12.11 SMAD2 SMAD3 TGFB1
7
Th1 Differentiation Pathway 65
Show member pathways
 12.07 SMAD2 SMAD3 TGFB1
8
Wnt / Hedgehog / Notch 4
12.05 SMAD2 SMAD3 TGFB1
9
Cell cycle Role of SCF complex in cell cycle regulation 22
Show member pathways
 12.02 SMAD2 SMAD3 TGFB1
10
Colorectal Cancer Metastasis 64
11.97 SMAD2 SMAD3 TGFB1
11
Cellular senescence (KEGG) 37
11.95 SMAD2 SMAD3 TGFB1
12
Hippo signaling pathway 37
11.92 SMAD2 SMAD3 TGFB1
13
FoxO signaling pathway 37
Show member pathways
 11.85 SMAD2 SMAD3 TGFB1
14
SMAD Signaling Network 64
11.84 SMAD2 SMAD3 TGFB1
15
TGF-beta Signaling Pathway (WikiPathways) 1
11.82 SMAD2 SMAD3 TGFB1
16
AGE-RAGE signaling pathway in diabetic complications 37
11.68 SMAD2 SMAD3 TGFB1
17
TGF-beta Signaling Pathways 65
11.65 SMAD2 SMAD3 TGFB1
18
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.62 SMAD2 SMAD3 TGFB1
19
Loss of Function of SMAD2/3 in Cancer 66
Show member pathways
 11.52 SMAD2 SMAD3 TGFB1
20
Development_TGF-beta receptor signaling 22
11.47 SMAD2 SMAD3 TGFB1
21
TGF-beta receptor signaling activates SMADs 66
Show member pathways
 11.43 SMAD2 SMAD3 TGFB1
22
TGF-beta Receptor Signaling (WikiPathways) 1
11.31 SMAD2 SMAD3 TGFB1
23
TGF-beta receptor signaling (Pathway Interaction Database) 1
11.21 SMAD2 SMAD3 TGFB1
24
Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling 1
11.13 SMAD2 SMAD3
25
Glypican 1 network 1
11.03 SMAD2 TGFB1
26
IL-2 Gene Expression in Activated and Quiescent T-Cells 64
Show member pathways
 11.02 SMAD2 SMAD3 TGFB1
27
Hypothesized Pathways in Pathogenesis of Cardiovascular Disease 1
10.99 SMAD2 SMAD3
28
Extracellular vesicle-mediated signaling in recipient cells 1
10.91 SMAD2 SMAD3 TGFB1
29
TGF-beta signaling pathway (KEGG) 37
10.85 DCN SMAD2 SMAD3 TGFB1
30
Regulation of cytoplasmic and nuclear SMAD2/3 signaling 1
10.83 SMAD2 SMAD3
31
TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition 1
10.39 SMAD2 SMAD3 TGFB1
Sources

GO Terms for Penile Disease

About this section

Cellular components related to Penile Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 SMAD protein complex GO:0071141 8.96 SMAD2 SMAD3
2 heteromeric SMAD protein complex GO:0071144 8.62 SMAD2 SMAD3

Biological processes related to Penile Disease according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.99 IFNA2 SMAD2 SMAD3 TGFB1
2 negative regulation of transcription, DNA-templated GO:0045892 9.96 IFNA2 PHB2 SMAD2 TGFB1
3 negative regulation of gene expression GO:0010629 9.86 IFNA2 SMAD2 TGFB1
4 protein stabilization GO:0050821 9.81 PEX19 PHB2 SMAD3
5 transforming growth factor beta receptor signaling pathway GO:0007179 9.79 SMAD2 SMAD3 TGFB1
6 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.74 SMAD2 SMAD3 TGFB1
7 SMAD protein signal transduction GO:0060395 9.72 SMAD2 SMAD3 TGFB1
8 extrinsic apoptotic signaling pathway GO:0097191 9.69 SMAD3 TGFB1
9 negative regulation of T cell proliferation GO:0042130 9.69 PDE5A TGFB1
10 gastrulation GO:0007369 9.68 SMAD2 SMAD3
11 mesoderm formation GO:0001707 9.68 SMAD2 SMAD3
12 positive regulation of bone mineralization GO:0030501 9.68 SMAD3 TGFB1
13 negative regulation of mitotic cell cycle GO:0045930 9.67 SMAD3 TGFB1
14 embryonic cranial skeleton morphogenesis GO:0048701 9.67 SMAD2 SMAD3
15 positive regulation of protein import into nucleus GO:0042307 9.67 SMAD3 TGFB1
16 developmental growth GO:0048589 9.66 SMAD2 SMAD3
17 protein import into nucleus, translocation GO:0000060 9.66 PHB2 TGFB1
18 embryonic pattern specification GO:0009880 9.65 SMAD2 SMAD3
19 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.65 SMAD3 TGFB1
20 cell-cell junction organization GO:0045216 9.64 SMAD3 TGFB1
21 signal transduction involved in regulation of gene expression GO:0023019 9.63 SMAD2 SMAD3
22 negative regulation of protein localization to plasma membrane GO:1903077 9.63 MRAP TGFB1
23 positive regulation of epithelial to mesenchymal transition GO:0010718 9.63 SMAD2 SMAD3 TGFB1
24 activin receptor signaling pathway GO:0032924 9.62 SMAD2 SMAD3
25 lens fiber cell differentiation GO:0070306 9.62 SMAD3 TGFB1
26 response to cholesterol GO:0070723 9.61 SMAD2 TGFB1
27 ureteric bud development GO:0001657 9.61 SMAD2 SMAD3 TGFB1
28 nodal signaling pathway GO:0038092 9.6 SMAD2 SMAD3
29 primary miRNA processing GO:0031053 9.59 SMAD2 SMAD3
30 pericardium development GO:0060039 9.58 SMAD2 SMAD3
31 embryonic foregut morphogenesis GO:0048617 9.58 SMAD2 SMAD3
32 common-partner SMAD protein phosphorylation GO:0007182 9.56 SMAD2 TGFB1
33 regulation of branching involved in mammary gland duct morphogenesis GO:0060762 9.54 PHB2 TGFB1
34 regulation of striated muscle tissue development GO:0016202 9.52 SMAD3 TGFB1
35 positive regulation of exit from mitosis GO:0031536 9.51 PHB2 TGFB1
36 endoderm development GO:0007492 9.5 SMAD2 SMAD3 TGFB1
37 mammary gland branching involved in thelarche GO:0060744 9.49 PHB2 TGFB1
38 positive regulation of extracellular matrix assembly GO:1901203 9.48 SMAD3 TGFB1
39 wound healing GO:0042060 9.46 DCN SMAD2 SMAD3 TGFB1
40 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.43 SMAD2 SMAD3 TGFB1
41 evasion or tolerance of host defenses by virus GO:0019049 9.4 SMAD3 TGFB1
42 paraxial mesoderm morphogenesis GO:0048340 9.37 SMAD2 SMAD3
43 SMAD protein complex assembly GO:0007183 9.13 SMAD2 SMAD3 TGFB1
44 regulation of binding GO:0051098 8.8 SMAD2 SMAD3 TGFB1

Molecular functions related to Penile Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 R-SMAD binding GO:0070412 9.43 SMAD2 SMAD3
2 enhancer binding GO:0035326 9.4 SMAD2 SMAD3
3 co-SMAD binding GO:0070410 9.37 SMAD2 SMAD3
4 type I transforming growth factor beta receptor binding GO:0034713 9.32 SMAD2 TGFB1
5 primary miRNA binding GO:0070878 9.26 SMAD2 SMAD3
6 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.16 SMAD2 SMAD3
7 transforming growth factor beta receptor binding GO:0005160 9.13 SMAD2 SMAD3 TGFB1
8 protein N-terminus binding GO:0047485 8.92 DCN PEX19 PHB2 TGFB1
Sources

Sources for Penile Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....